Department of Internal Medicine, National Hospital Organization Tochigi Medical Center, 1-10-37, Nakatomatsuri, Utsunomiya, Tochigi, 3208580, Japan.
Department of Pharmacy, National Hospital Organization Tochigi Medical Center, 1-10-37, Nakatomatsuri, Utsunomiya, Tochigi, 3208580, Japan.
BMC Geriatr. 2018 Apr 17;18(1):96. doi: 10.1186/s12877-018-0788-1.
Few studies have evaluated the characteristics of elderly patients with polypharmacy refusing deprescribing. The aim of this study was to evaluate the prevalence of potentially inappropriate medication (PIM) use in elderly patients accepting and refusing a deprescribing intervention and to investigate factors associated with deprescribing refusal.
We conducted a retrospective cross-sectional study by analyzing the electronic medical records from a single hospital. All consecutive patients aged 65 years or older who reported the use of five or more medications upon admission to the orthopedic ward from January 2015 to December 2016 and who were approached by a pharmacist for polypharmacy screening were included. Patients who had provided consent for the deprescribing intervention by the internal medicine physicians were defined as the acceptance group, and patients who did not were defined as the refusal group. The primary outcome was the use of any PIMs at admission, based on the 2015 American Geriatric Society Beers Criteria. Using multivariable logistic regression, predictive factors of refusing deprescribing were also evaluated.
During the study period, 136 patients were eligible. Of those, 82 patients (60.3%) accepted the deprescribing intervention, and 54 patients (39.7%) declined the intervention. The mean age of all the patients was 81.1 years, and the mean number of medications at admission was 9.3. The overall proportion of patients taking any PIMs at admission was 77.2%. The proportion of patients taking any PIMs at admission was not different between the acceptance and refusal groups (78.0% and 75.9%, respectively; p = 0.84). None of the measured characteristics, including age, gender, residential status, comorbidity, alcohol use, smoking status, number of medications, or number of PIMs, were found to be associated with deprescribing refusal.
The prevalence of any PIM use did not differ among elderly orthopedic patients with polypharmacy according to refusal or acceptance of the deprescribing intervention. Furthermore, none of the analyzed characteristics were found to be associated with deprescribing refusal. Given the high prevalence of PIM use, a strategy is needed for combating polypharmacy among elderly patients reluctant to undergo deprescribing.
很少有研究评估拒绝药物精简治疗的老年多药使用者的特征。本研究旨在评估接受和拒绝药物精简治疗的老年患者中潜在不适当药物(PIM)使用的患病率,并调查与拒绝药物精简相关的因素。
我们通过分析单家医院的电子病历进行了回顾性横断面研究。所有连续患者年龄在 65 岁或以上,在 2015 年 1 月至 2016 年 12 月期间,因骨科病房入院时报告使用五种或五种以上药物,并由药剂师进行药物精简筛查,均纳入研究。如果内科医生同意进行药物精简治疗,患者被定义为接受组,如果不同意,则定义为拒绝组。主要结局是根据 2015 年美国老年医学会 Beers 标准,入院时使用任何 PIMs。使用多变量逻辑回归,还评估了拒绝药物精简的预测因素。
在研究期间,共有 136 名患者符合条件。其中,82 名患者(60.3%)接受了药物精简治疗,54 名患者(39.7%)拒绝了该治疗。所有患者的平均年龄为 81.1 岁,入院时的平均用药数为 9.3。入院时服用任何 PIM 的患者总体比例为 77.2%。接受组和拒绝组入院时服用任何 PIM 的患者比例无差异(分别为 78.0%和 75.9%;p=0.84)。所测量的特征,包括年龄、性别、居住状况、合并症、饮酒、吸烟状况、用药数量或 PIM 数量,均与药物精简治疗拒绝无关。
根据拒绝或接受药物精简治疗,骨科老年多药使用者中任何 PIM 使用的患病率无差异。此外,未发现分析的特征与药物精简治疗拒绝有关。鉴于 PIM 使用的高患病率,需要制定策略来解决拒绝药物精简治疗的老年患者的药物过量问题。